IL132125A0 - Use of 5-(4-(2-methyl-n- (2-pyridyl) amino) - ethoxy) 2, 4- thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes - Google Patents

Use of 5-(4-(2-methyl-n- (2-pyridyl) amino) - ethoxy) 2, 4- thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes

Info

Publication number
IL132125A0
IL132125A0 IL13212598A IL13212598A IL132125A0 IL 132125 A0 IL132125 A0 IL 132125A0 IL 13212598 A IL13212598 A IL 13212598A IL 13212598 A IL13212598 A IL 13212598A IL 132125 A0 IL132125 A0 IL 132125A0
Authority
IL
Israel
Prior art keywords
thiazolidinedione
pyridyl
ethoxy
amino
methyl
Prior art date
Application number
IL13212598A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL132125A0 publication Critical patent/IL132125A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13212598A 1997-05-15 1998-05-14 Use of 5-(4-(2-methyl-n- (2-pyridyl) amino) - ethoxy) 2, 4- thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes IL132125A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/856,987 US5874454A (en) 1993-09-15 1997-05-15 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PCT/US1998/010113 WO1998051305A1 (en) 1997-05-15 1998-05-14 Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes

Publications (1)

Publication Number Publication Date
IL132125A0 true IL132125A0 (en) 2001-03-19

Family

ID=25324901

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13212598A IL132125A0 (en) 1997-05-15 1998-05-14 Use of 5-(4-(2-methyl-n- (2-pyridyl) amino) - ethoxy) 2, 4- thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes

Country Status (14)

Country Link
US (1) US5874454A (is)
EP (1) EP0981346A1 (is)
JP (1) JP2001525827A (is)
KR (1) KR20010012556A (is)
AU (1) AU731690B2 (is)
BR (1) BR9809120A (is)
CA (1) CA2282473A1 (is)
HU (1) HUP0003397A3 (is)
IL (1) IL132125A0 (is)
IS (1) IS5177A (is)
NO (1) NO995549D0 (is)
PL (1) PL336764A1 (is)
WO (1) WO1998051305A1 (is)
ZA (1) ZA984084B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
RU2665969C1 (ru) * 2017-05-04 2018-09-05 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения синдрома поликистозных яичников

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP3544659B2 (ja) * 1990-02-09 2004-07-21 ファルマシア・アンド・アップジョン・カンパニー インスリン感性化剤類の高血圧治療のための使用
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
ES2092112T3 (es) * 1991-06-25 1996-11-16 Pfizer Agentes hipoglicemicos de tiazolidindiona.
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)

Also Published As

Publication number Publication date
JP2001525827A (ja) 2001-12-11
ZA984084B (en) 1998-11-20
AU731690B2 (en) 2001-04-05
KR20010012556A (ko) 2001-02-15
NO995549L (no) 1999-11-12
WO1998051305A1 (en) 1998-11-19
NO995549D0 (no) 1999-11-12
PL336764A1 (en) 2000-07-17
CA2282473A1 (en) 1998-11-19
BR9809120A (pt) 2000-08-01
HUP0003397A2 (hu) 2002-01-28
EP0981346A1 (en) 2000-03-01
AU7494998A (en) 1998-12-08
US5874454A (en) 1999-02-23
IS5177A (is) 1999-09-10
HUP0003397A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
AU4072799A (en) 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
SI1231918T1 (en) Novel composition based on a thiazolidinedione and metformin and use
EP0908186A3 (en) Method for treating pain
HUP0102656A3 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders and medicaments containing them
WO2002064210A3 (en) Combination therapy comprising anti-diabetic and anticonvulsant agents
AU2003275716A1 (en) 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same
AU2001280486A1 (en) Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
IL132125A0 (en) Use of 5-(4-(2-methyl-n- (2-pyridyl) amino) - ethoxy) 2, 4- thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes
ZA985030B (en) Composition for use in personal care.
AU5234199A (en) Composition useful for softening, cleaning, and personal care applications
HK1045154B (zh) 唑烷二酮衍生物及其用作抗糖尿病藥的應用
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
AU2002349299A1 (en) Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
CA2200126A1 (en) Treatment and prophylaxis of pancreatitis
AP9901696A0 (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione
AP2000001734A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL146077A0 (en) Thiazolidinedione derivative and its use as antidiabetic
AU2002215059A1 (en) Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
SI1315723T1 (en) The hydrochloride salt of 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
AU5121796A (en) 2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
HUP0301799A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide for treating diabetes mellitus, process for preparation thereof and pharmaceutical composition containing the same
GB2353524B (en) Piezoelectric ceramic composition and piezoelectric ceramic device using the same
GB2350359B (en) Piezoelectric ceramic composition and piezoelectric ceramic element using the same
EP0792150A4 (en) 2- (2,3,5,6-TETRAFLUORO-4-PYRIDYL) -1,2,5-THIADIAZOLODIN-3-ON 1,1-DIOXIDE AND AGENTS AND METHOD FOR USE THEREOF